J C Hartman
Overview
Explore the profile of J C Hartman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
124
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Reduced nitric oxide reactivity of a new recombinant human hemoglobin attenuates gastric dysmotility
Hartman J, Argoudelis G, Doherty D, Lemon D, Gorczynski R
Eur J Pharmacol
. 1999 Jan;
363(2-3):175-8.
PMID: 9881587
The objective of this investigation was to compare the gastric motility effects of two recombinant hemoglobin variants, rHb1.1, and rHb3011, the latter having decreased nitric oxide reactivity via mutagenic alteration....
2.
Wall T, Linseman D, Hartman J
Eur J Pharmacol
. 1996 Jun;
306(1-3):165-74.
PMID: 8813629
Isolated rat neonatal cardiac myocytes were subjected to immersion in hypoxic (PO2 < 2 mm Hg), glucose-free Tyrode's solution for 5 h followed by concomitant reoxygenation and staining with the...
3.
Hartman J
Ann Thorac Surg
. 1995 Sep;
60(3):789-92.
PMID: 7545893
Background: The angiotensin-converting enzyme inhibitor ramiprilat has been previously demonstrated to protect myocardium from ischemia/reperfusion injury. The objective of these investigations was to examine the roles of bradykinin, angiotensin II,...
4.
Hartman J, Anderson D, Wiltse A, Lane C, Rosenbloom C, Manning A, et al.
Cardiovasc Res
. 1995 Jul;
30(1):47-54.
PMID: 7553723
Objective: A blocking monoclonal antibody to intercellular adhesion molecule-1 (ICAM-1), CL18/6, previously has been demonstrated to inhibit neutrophil attachment to isolated vascular endothelium and cardiomyocytes. Due to the well known...
5.
Linseman D, Wall T, Hartman J
J Mol Cell Cardiol
. 1994 Sep;
26(9):1249-57.
PMID: 7815467
Neonatal rat cardiac myocytes were subjected to 5 h of hypoxia (PO2 < 5 mmHg) in glucose-free, modified Tyrodes solution. Prior to hypoxic exposure, cells were pretreated for 90 min...
6.
Hartman J, Kurc G, Hullinger T, Wall T, Sheehy R, Shebuski R
J Pharmacol Exp Ther
. 1994 Sep;
270(3):1071-6.
PMID: 7523655
The objective of this investigation was to determine the role of nitric oxide synthase in the action of the angiotensin-converting enzyme inhibitor, ramiprilat, to reduce myocardial ischemia/reperfusion injury. Ramiprilat, the...
7.
Wall T, Sheehy R, Hartman J
J Pharmacol Exp Ther
. 1994 Aug;
270(2):681-9.
PMID: 8071859
The role of bradykinin in the cardioprotective action of ischemic preconditioning was investigated in an anesthetized, open-chest rabbit model of acute coronary occlusion. A branch of the left main coronary...
8.
Hartman J, Olszanski D, Hullinger T, Brunden M
J Pharmacol Toxicol Methods
. 1994 Jun;
31(3):153-60.
PMID: 8068977
The objective of this investigation was to validate a transit-time ultrasound blood flow metering system in vivo. Implanted chronically and acutely on the ascending aorta of the dog, the transit-time...
9.
Kersten J, Hartman J, Pagel P, Warltier D
Adv Pharmacol
. 1994 Jan;
31:269-84.
PMID: 7873418
No abstract available.
10.
Hartman J, Wall T, Hullinger T, Shebuski R
J Cardiovasc Pharmacol
. 1993 Jun;
21(6):996-1003.
PMID: 7687728
We wished to determine, using a novel specific antagonist of BK2, HOE 140, (a) if the angiotensin-converting enzyme (ACE) inhibitor, ramiprilat, reduces myocardial infarct size in a well-established animal model...